首页> 美国卫生研究院文献>The Journal of Clinical Investigation >Origin of urinary nonconjugated 19-nor-deoxycorticosterone and metabolism of infused radiolabeled 19-nor-deoxycorticosterone in men and women.
【2h】

Origin of urinary nonconjugated 19-nor-deoxycorticosterone and metabolism of infused radiolabeled 19-nor-deoxycorticosterone in men and women.

机译:男女非尿液非共轭19-去氧皮质酮的起源和经放射性标记的19-去氧皮质酮的代谢。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

It is known that 19-nor-deoxycorticosterone (19-nor-DOC) is a potent mineralocorticosteroid that is present in urine of rats and humans in a free, i.e., nonconjugated, form. In some forms of hypertension in rats, the levels of free 19-nor-DOC in urine are increased compared with those in urine of normotensive animals. Yet, despite the potential importance of this mineralocorticosteroid in the pathogenesis of certain forms of hypertension, little is known of its site of origin or metabolism. In the present investigation, we evaluated the metabolism of intravenously infused [3H]19-nor-DOC and the possibility that 19-nor-DOC was formed from plasma DOC. We found that the metabolism of [3H]19-nor-DOC infused intravenously in men and women was similar to that of DOC with important exceptions. The majority of the radiolabeled urinary metabolites of intravenously infused [3H]19-nor-DOC were excreted in urine as glucuronosides. Little radioactivity, infused as [3H]19-nor-DOC, was recovered in urine as nonconjugated or sulfoconjugated steroids. There was no free radiolabeled 19-nor-DOC in urine after the simultaneous infusion of [3H]19-nor-DOC and [14C]DOC. A major metabolite of [3H]19-nor-DOC in urine was 19-nor-DOC-21-glucuronoside, whereas little or no intravenously infused radiolabeled DOC was excreted as radiolabeled DOC-glucuronoside. We also found that intravenously infused [14C]DOC was not converted to urinary [14C]19-nor-DOC (glucuronoside) and that other tritium-labeled metabolites of infused [3H]19-nor-DOC contained no carbon-14. The production rate of 19-nor-DOC, computed from the specific activity of urinary 19-nor-DOC (glucuronoside), in one normal man was 16 micrograms/d and in the two women of this study, it was 10 micrograms/d. These findings are supportive of the proposition that free urinary 19-nor-DOC is not formed from plasma DOC; it may be formed in kidney from a precursor other than DOC or it may be formed nonenzymatically in kidney or urine from a precursor such as 19-oic-DOC.
机译:已知19-去脱氧皮质酮(19-去-DOC)是有效的矿物质皮质类固醇,其以游离即非结合形式存在于大鼠和人的尿液中。在某些形式的大鼠高血压中,与正常血压动物尿液相比,尿液中游离19-nor-DOC的含量增加。然而,尽管这种盐皮质激素在某些形式的高血压的发病机理中具有潜在的重要性,但对其起源或代谢部位知之甚少。在本研究中,我们评估了静脉输注[3H] 19-nor-DOC的代谢以及由血浆DOC形成19-nor-DOC的可能性。我们发现,静脉注射[3H] 19-nor-DOC的代谢在男女中与DOC相似,但有重要的例外。静脉内输注的[3H] 19-nor-DOC放射性标记的尿代谢产物大多数以葡萄糖醛酸苷的形式排泄在尿中。以[3H] 19-nor-DOC的形式注入的少量放射性以非结合类固醇或磺基结合类固醇的形式在尿液中回收。同时输注[3H] 19-nor-DOC和[14C] DOC后,尿液中没有游离的放射性标记的19-nor-DOC。尿液中[3H] 19-nor-DOC的主要代谢产物是19-nor-DOC-21-葡萄糖醛酸苷,而很少或没有静脉输注的放射性标记的DOC被排泄为放射性标记的DOC-葡萄糖醛酸苷。我们还发现,静脉输注的[14C] DOC不能转化为尿液[14C] 19-nor-DOC(葡萄糖苷),并且注入的[3H] 19-nor-DOC的其他other标记代谢物均不含碳14。根据尿液19-nor-DOC(葡萄糖醛酸苷)的比活计算出的19-nor-DOC的生产率,在一名正常男性中为16微克/天,在本研究的两名女性中为19微克/天。 。这些发现支持以下观点:血浆DOC没有形成游离尿19-nor-DOC。它可以由除DOC以外的前体在肾脏中形成,也可以由19-oic-DOC等前体在肾脏或尿液中非酶促形成。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号